Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Ischemic Stroke
Interventions: donepezil, placebo; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Warren, Ohio • Pittsburgh, Pennsylvania

Conditions: Cesarean Delivery
Interventions: Metoclopramide, Phenylephrine infusion, Combination Group; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550, placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 33
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Upland, California + 26 more

Conditions: Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions: benralizumab, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Knee Osteoarthritis
Interventions: Realigning knee brace and custom orthodic, Non realigning knee brace and flat orthodic; Device
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson's Disease
Interventions: UCB0599, Placebo; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Long Beach, California • Bay Harbor Islands, Florida • DeLand, Florida + 3 more

Conditions: Chronic Low Back Pain, Osteoarthritis
Interventions: Fasinumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 56
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 47 more

Conditions: Smoking, Nicotine Dependence
Interventions: Naltrexone, Bupropion; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV, Salivary Gland Disease, Benign Lymphoepithelial Lesion
Interventions: Ciprofloxacin, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Dental Caries
Interventions: C16G2 Strip, Placebo Strip; Drug · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Kalispell, Montana • Bedford, Texas • Irving, Texas

Conditions: Ankle Sprain
Interventions: Diclofenac epolamine, Placebo; Drug · Other
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 658 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 31
States / cities: Birmingham, Alabama • Goodyear, Arizona • Carlsbad, California + 26 more

Conditions: Systemic Lupus Erythematosus
Interventions: Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin, Placebo for Voclosporin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 6 more

Conditions: Alzheimer Disease
Interventions: Lithia water, Transcranial Magnetic stimulation; Dietary Supplement · Device
Lead sponsor: American Society Of Thermalism And Climatology Inc; Other
Eligibility: 50 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Hypertension
Interventions: Febuxostat, Placebo; Drug
Lead sponsor: Paul N. Hopkins; Other
Eligibility: 18 Years to 60 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Smell Dysfunction, Olfactory Disorder, Long COVID
Interventions: Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST), Placebo Smell Training (PBO); Device · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypertension and Coronary Artery Disease
Interventions: Celecoxib, placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 50 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: Gainesville, Florida • Houston, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: Ambrisentan, Placebo, Sildenafil, Tadalafil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 30
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: Myeloma
Interventions: Telephone Questionnaire; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 78 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis
Interventions: Active Device (Torino II), Sham Device (Torino II); Device
Lead sponsor: Center for Joint Surgery and Sports Medicine, Maryland; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Hagerstown, Maryland

Conditions: Neuropathic Pain
Interventions: oxytocin 100 micrograms, Normal Saline (preservative free); Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: COVID-19
Interventions: Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Atopic Dermatitis
Interventions: Placebo, JNJ-26113100 (50 mg) once daily, JNJ-26113100 (100 mg) once daily, JNJ-26113100 (100 mg) twice daily, JNJ-26113100 (250 mg) twice daily; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Huntsville, Alabama • Los Angeles, California • Sacramento, California + 16 more

Conditions: Obstructive Sleep Apnea, Delayed Emergence From Anesthesia
Interventions: Modafinil, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Chronic Kidney Disease
Interventions: BAY3283142, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 24
States / cities: Huntsville, Alabama • Chula Vista, California • San Dimas, California + 20 more

Search by objective public record fields.

Enhancing Rehabilitation After Stroke

Prevention of Intraoperative Nausea and Vomiting During Cesarean Section

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

Trial of Realignment Therapy for Treatment of Medial Knee Osteoarthritis

A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain

BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent

A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application

Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

LIWA for Treatment of Alzheimer Patients

Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)

Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)

Effect of Celecoxib on Markers of Vascular Inflammation

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

Long-Term Follow Up Study for AMD3100 Patients

Use of Pulsed Electromagnetic Fields for Postoperative Knee Pain

Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea

A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease